(800) 424-6690

Are You a Rocket Pharmaceuticals
Shareholder?

A class action lawsuit was recently filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) on behalf of purchasers of Rocket Pharmaceuticals securities.

View our terms of service and privacy policy.

Lawsuit Eligibility

Rocket Pharmaceuticals shareholders who purchased shares from February 27, 2025 through May 26, 2025.

Lead Plaintiff Deadline

August 11, 2025

About the Lawsuit

The case was filed in the U.S. District Court for the District of New Jersey and alleges that Rocket Pharmaceuticals misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program.

The lawsuit alleges that the Company failed to inform investors of a substantial protocol change, specifically the addition of a novel immunomodulatory agent, prior to a serious adverse event (SAE) and subsequent FDA clinical hold. Following the Company’s disclosure of a patient death in the trial, RCKT shares fell nearly 37%, from $6.27 on May 23, 2025, to $2.33 on May 27, 2025.

Investors who purchased or acquired Rocket Pharmaceuticals securities from February 27, 2025 through May 26, 2025, may no later than August 11, 2025, seek to be appointed as a lead plaintiff representative of the class.

Berger Montague has been a pioneer in shareholder litigation since its founding in 1970. The Firm has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.